NCT07284927

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.

Conditions

• Non-Hodgkin Lymphoma
• Acute Lymphoblastic Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	LV009 Injection	Eligible subjects who pass the screening process after providing signed informed consent will receive an infusion of LV009 Injection.

Timeline

• Start date: 2025-12-03
• Primary completion: 2026-12-03
• Completion: 2027-12-03
• First posted: 2025-12-16
• Last updated: 2025-12-16

Locations

1 site across 1 country: China